-
Mashup Score: 3
A panel of experts discussed their institutions’ practices for administering bispecific antibodies, BCMA or GPRC5D, to patients with multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 3
Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Belantamab Mafodotin–Based Combos Win Japanese Approval for R/R Myeloma #mmsm #oncology https://t.co/kgcn7bXnFh
-
-
Mashup Score: 6Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma - 28 day(s) ago
A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma @MoffittNews @JCO_ASCO #mmsm #oncology https://t.co/eCEuIRFOd1
-
-
Mashup Score: 4Post Hoc Analysis of Pooled PERSEUS and GRIFFIN Data Support D-VRd in Transplant-Eligible Myeloma - 1 month(s) ago
D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.
Source: www.onclive.comCategories: General Medicine NewsTweet-
According to a post hoc analysis of pooled PERSEUS and GRIFFIN data, D-VRd led to a PFS benefit and deeper responses vs VRd followed by lenalidomide alone in patients with transplant-eligible myeloma. #mmsm #oncology https://t.co/ZWxhiPmlC7
-
-
Mashup Score: 4Post Hoc Analysis of Pooled PERSEUS and GRIFFIN Data Support D-VRd in Transplant-Eligible Myeloma - 1 month(s) ago
D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.
Source: www.onclive.comCategories: General Medicine NewsTweet-
According to a post hoc analysis of pooled PERSEUS and GRIFFIN data, D-VRd led to a PFS benefit and deeper responses vs VRd followed by lenalidomide alone in patients with transplant-eligible myeloma. #mmsm #oncology https://t.co/ZWxhiPmlC7
-
-
Mashup Score: 8Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma - 1 month(s) ago
Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma #mmsm #oncology https://t.co/hEjcNjUZVw
-
-
Mashup Score: 2China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma - 4 month(s) ago
China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma #mmsm #oncology https://t.co/EwgGsaDN9A
-
-
Mashup Score: 7
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Hear @freemanlciaraMD of @MoffittNews discuss the phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma. #mmsm #oncology Watch here: https://t.co/YqEd3rop30
-
-
Mashup Score: 2China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma - 4 month(s) ago
China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma #mmsm #oncology https://t.co/EwgGsaDN9A
-
-
Mashup Score: 3Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma - 4 month(s) ago
Subcutaneous isatuximab plus Pd led to a noninferior ORR and observed concentration before dosing at steady state vs IV isatuximab plus Pd in RRMM.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma @mayoclinic #mmsm #oncology https://t.co/GmeyqLaogX
-
A panel of experts in hematologic cancers discussed their institutions’ practices for administering bispecific antibodies, specifically BCMA or GPRC5D, to patients with multiple myeloma. #mmsm #ONCOLOGY https://t.co/THVyBoQLXb